Editas edits pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

One of the early gene editing hopefuls, Editas Medicine, has struggled to keep its ship on the right path. The biotech’s latest woes include pipeline cuts, layoffs and the CSO’s exit.